跳轉至內容
Merck
全部照片(1)

Key Documents

Y0000866

舍曲林

European Pharmacopoeia (EP) Reference Standard

同義詞:

盐酸舍曲林 盐酸盐, (1S,4S)-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺 盐酸盐

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H17NCl2 · HCl
CAS號碼:
分子量::
342.69
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

sertraline

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

ClC1=C(Cl)C=CC([C@H]2C3=C(C=CC=C3)[C@@H](NC)CC2)=C1.[H]Cl

InChI

1S/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H/t12-,17-;/m0./s1

InChI 密鑰

BLFQGGGGFNSJKA-XHXSRVRCSA-N

基因資訊

human ... SLC6A4(6532)

尋找類似的產品? 前往 產品比較指南

一般說明

Sertraline hydrochloride is a SSRI i.e selective serotonin reuptake inhibitor. It is mainly used in treating psychiatric disorders. It also is effective in treating hypotension occurring in disorders like neurocardiogenic syncope and idiopathic orthostatic hypotension which is affected by autonomic dysfunction.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Sertraline for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

选择性 5-羟色胺再摄取抑制剂,抗抑郁药。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - STOT RE 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Latif Moradveisi et al.
The British journal of psychiatry : the journal of mental science, 202(3), 204-211 (2013-02-09)
Behavioural activation might be a viable alternative to antidepressant medication for major depressive disorder. To compare the effectiveness of behavioural activation and treatment as usual (TAU, antidepressant medication) for major depressive disorder in routine clinical practice in Iran. Patients with
Sofia Hult Lundh et al.
Human molecular genetics, 22(17), 3485-3497 (2013-05-24)
Psychiatric symptoms such as depression and anxiety are important clinical features of Huntington's disease (HD). However, the underlying neurobiological substrate for the psychiatric features is not fully understood. In order to explore the biological origin of depression and anxiety in
Alastair J Flint et al.
BMC psychiatry, 13, 38-38 (2013-01-29)
Psychotic depression (PD) is a severe disabling disorder with considerable morbidity and mortality. Electroconvulsive therapy and pharmacotherapy are each efficacious in the treatment of PD. Expert guidelines recommend the combination of antidepressant and antipsychotic medications in the acute pharmacologic treatment
Kara Zivin et al.
The American journal of psychiatry, 170(6), 642-650 (2013-05-04)
A recent Food and Drug Administration (FDA) warning cautioned that citalopram dosages exceeding 40 mg/day may cause abnormal heart rhythms, including torsade de pointes. The authors assessed relationships between citalopram use and ventricular arrhythmias and mortality. A cohort study was
Aquatic ecotoxicity of the selective serotonin reuptake inhibitor sertraline hydrochloride in a battery of freshwater test species.
Minagh E
Ecotox. Environ. Safety, 72(2), 434-440 (2009)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務